Figure 1. Baseline examination, 1 month after the onset of the patient’s initial symptoms (April 2021) and 1st follow-up visit (May 2021). The patient received intravenous (IV) corticosteroids (6 mg dexamethasone once daily for 1 week), followed by per os methylprednisolone 16 mg with gradual tapering (16 mg once daily for 3 days, 8 mg once daily for 3 days, 4 mg once daily for 3 days, and 2 mg once daily for 3 days). (A) Optical coherence tomography (OCT) scan of the right eye showing a small amount of subretinal fluid (SRF) in April 2021. (B) OCT scan of the left eye showing SRF in April 2021. (C) OCT scan of the right eye showing a small amount of SRF and the development of a small amount of subretinal fibrin-like material in May 2021. (D) OCT scan of the left eye showing a disruption of the RPE, with no visible SRF (May 2021). (E) Fluorescein fundus angiography (FFA) of the right eye showing a focus of pin point hyperfluorescence temporally to the macula at 00.28.19 (in May 2021). (F) FFA of the right eye showing smokestack-like leakage temporally to the macula at 03.52.29 (in May 2021). (G) FFA of the left eye revealed 2 small staining points (yellow arrows) in the macular area, 1 at the inferior macula and one superotemporal to the optic nerve at 00.59.29 (in May 2021). (H) FFA of the left eye revealed 2 small staining points (yellow arrows) in the macular area, 1 at the inferior macula and 1 superotemporal to the optic nerve at 02.37.00 (in May 2021).